Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial.

By J. Shepherd, G. Blauw, M. Murphy, E. Bollen, B. Buckley, S. Cobbe, Ian Ford, A. Gaw, M. Hyland, J. Jukema and 10 more. The Lancet, 2002

3,323 citations recorded by the source corpus.

Subfields: Cancer Research, Endocrinology, Diabetes and Metabolism, Surgery

View Paper: https://www.semanticscholar.org/paper/3743df65c4171c6950e7343296f35d5772c82581

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. I. Graham
2. J. Armitage
3. George Davey Smith
4. R. Collins
5. M. Law
6. C. Iadecola
7. S. Grundy
8. P. Ridker

In Endocrinology, Diabetes and Metabolism

1. I. Graham
2. S. Grundy
3. P. Ridker
4. J. Armitage
5. George Davey Smith
6. C. Iadecola
7. P. Poirier
8. Massimo F. Piepoli

In Surgery

1. I. Graham
2. S. Grundy
3. P. Ridker
4. J. Armitage
5. George Davey Smith
6. R. Collins
7. M. Law
8. Peter Libby

Citations in the corpus

• Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. (2004, background): “HPS and PROSPER results add support for benefit of LDL-lowering therapy in older persons.”
• Statins and cancer prevention (2005, neutral): “Randomized controlled trials Several large RCTs of single-agent statins for the prevention of CVD included secondary endpoints of overall cancer incidence and mortality and the incidence of certain specific cancer”